Business
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
CAMBRIDGE, Mass., May 12, 2026--Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited ("Impetis"), a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor.
About this update from Vyome Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":368,"height":350,"url":"https://media.zenfs.com/en/business-wire.com/c1eb04b56793538ac4804c85eb2dd2ae"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/p5FhJaNmGYkVR6e44mxu7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY3MQ--/https://media.zenfs.com/en/business-wire.com/c1eb04b56793538ac4804c85eb2dd2ae","width":368,"height":350},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/siCGKWSZB6n6Ttc4wYKKtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTYwOQ--/https://media.zenfs.com/en/business-wire.com/c1eb04b56793538ac4804c85eb2dd2ae","width":368,"height":350}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Vyome has signed an agreement with Impetis, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market¹","length":171,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"These next-generation JAK inhibitors are designed for higher selectivity, with the potential to improve safety versus earlier pan-JAK approaches","length":144,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The transaction reinforces Vyome’s ability to source differentiated innovation across the US–India corridor and translate it into strategic value","length":145,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Capital-efficient, commercialization-linked structure and future development expected through non-dilutive pathways, preserving focus on VT-1953 execution.","length":155,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":615,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., May 12, 2026--(BUSINESS WIRE)--Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited ("Impetis"), a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor.","length":346,"tagName":"p"},{"type":"text","content":"Janus kinase (JAK) inhibitors are immunomodulatory drugs that treat autoimmune and inflammatory conditions by blocking JAK enzymes. Several JAK inhibitors are FDA-approved to treat a wide range of disease conditions, includin...